Hemodia
FranceWho owns Hemodia?
Hemodia is a French MedTech company, currently owned by LBO France since 2025 and 2 other investors. It changed hands in 2025, when iXO Private Equity sold.
Hand-verified · updated 2026-09-30
Open JSON · CC-BY
Key facts
- ·Co-held by Multicroissance, Africinvest Europe and LBO France since 2022.
- ·4 distinct PE sponsors across ownership cycles.
Ownership history
4 ownership periods · co-invest detected
iXO Private Equity sold Hemodia to LBO France in 2025 after 6 years.
More from LBO France Small Cap
Other portfolio companies in the same fund.
More PE-backed in MedTech
Comparable medtech deals from other GPs.
US
GermanyQuestions
Who owns Hemodia?
Hemodia is currently owned by LBO France, Multicroissance and 1 other, through LBO France Small Cap, since 2025.
When did LBO France and 2 others acquire Hemodia?
LBO France and 2 others acquired Hemodia in 2025.
Who did Hemodia sell to?
iXO Private Equity sold Hemodia to LBO France in 2025 (Secondary).
Who has owned Hemodia over time?
Hemodia has been through 4 private-equity ownership periods: iXO Private Equity · via FIP APL 2015 · 2019–2025 · sold to LBO France · (Secondary); Multicroissance · via Multicroissance SAS SCR · since 2022; Africinvest Europe · via Fonds Franco-Africain II (FFA2) · since 2022; LBO France · via LBO France Small Cap · 2025–2025.